放、化疗同步治疗鼻腔NK/T细胞淋巴瘤36例  

Concomitant chemoradiotherapy in 36 cases of nasal-type natural killer T cell lymphoma

作　　者：周晓娟[1] 王瑾[1] 许峰[1] 李平[1] 李志平[1] 卢铀[1] 

机构地区：[1]四川大学华西医院肿瘤放疗科,四川成都610041

出　　处：《重庆医学》2011年第16期1593-1595,共3页Chongqing medicine

摘　　要：目的评价放、化疗同步治疗鼻腔自然杀伤性T(NK/T)细胞淋巴瘤的疗效与耐受性。方法对36例初治鼻腔NK/T细胞淋巴瘤ⅠE～ⅡE期患者进行回顾性研究,患者均采用放、化疗同步治疗,放疗采用三维适形放疗技术,常规分割,计划肿瘤靶区(PGTV)56～60 Gy/28～30次,计划靶区(PTV)46～50 Gy/23～25次。化疗采用CHOP方案,21 d为1个周期,共化疗3～6个周期。结果 36例患者均完成放、化疗同步治疗及3～6周期化疗,其中24例(66.7%)如期完成,12例(33.3%)因不良反应暂停放疗;完全缓解31例(86.1%),部分缓解4例(11.1%);5年总生存率和无进展生存率分别为82.0%和63.2%。结论同步放、化疗能有效治疗鼻腔NK/T细胞淋巴瘤。Objective To evaluate the therapeutic effects and tolerability of concomitant chemoradiotherapy in nasal-type natural killer T（NK/T） cell lymphoma.Methods Retrospective study was used to analyze 36 cases of initial treatment for nasal-type NK/T cell lymphoma in stage ⅠE-ⅡE.All patients underwent concomitant chemotherapy and radiotherapy.3-dimensional conformal radiotherapy was employed using conventional fractionation,planning gross tumor volume（PGTV） 56-60 Gy/28-30 fractions and planning target volume（PTV） 46-50 Gy/23-25 fractions.As for chemotherapy,the CHOP regimen was adopted for a period of 3-6 cycles with each cycle lasting 21 days.Results All patients completed concomoitant chemoradiotherapy and 3-6 cycles of chemotherapy,24（66.7%） of them completed on schedule while 12（33.3%） obtained radiotherapy suspended due to adverse reaction;31 patients（86.1%） showed complete remission while 4（11.1%） showed partial remission;5-year overall survival rate and progression-free survival rate were 82.0% and 63.2%,respectively.Conclusion Concomoitant chemoradiotherapy can be effective in treating nasal-type NK/T cell lymphoma.

关 键 词：鼻肿瘤 淋巴瘤 T细胞 放射治疗 抗肿瘤联合化疗方案 不良反应 

分 类 号：R739.6[医药卫生—肿瘤]